Change in Bone Density and Reduction in Fracture Risk: A Meta‐Regression of Published Trials

• Published in: Journal of bone and mineral research 2019-04, Vol.34 (4), p.632-642
• Main Authors: Bouxsein, Mary L, Eastell, Richard, Lui, Li‐Yung, Wu, Lucy A, de Papp, Anne E, Grauer, Andreas, Marin, Fernando, Cauley, Jane A, Bauer, Douglas C, Black, Dennis M
• Format: Article
• Language: English
• Subjects: Absorptiometry, Photon; Bone Density; BONE MINERAL DENSITY; CLINICAL TRIAL; Clinical trials; Dual energy X-ray absorptiometry; Femur; Fractures; Health risk assessment; Hip; Hip Fractures - diagnostic imaging; Hip Fractures - metabolism; Hip Fractures - prevention & control; Humans; META‐REGRESSION; OSTEOPOROSIS; Osteoporosis - diagnostic imaging; Osteoporosis - metabolism; Osteoporosis - therapy; Osteoporotic Fractures - diagnostic imaging; Osteoporotic Fractures - metabolism; Osteoporotic Fractures - prevention & control; Randomized Controlled Trials as Topic; Risk Factors; Spinal Fractures - diagnostic imaging; Spinal Fractures - metabolism; Spinal Fractures - prevention & control; Spine (lumbar); SURROGATE; Vertebrae
• ISSN: 0884-0431; 1523-4681
• DOI: 10.1002/jbmr.3641

ABSTRACT Meta‐analyses conducted >15 years ago reported that improvements in bone mineral density (BMD) were associated with reduction in vertebral and nonvertebral fractures in osteoporosis trials. Numerous studies have been conducted since then, incorporating new therapies with different mechanisms of action and enrolling many more subjects. To extend these prior analyses, we conducted a meta‐regression of 38 placebo‐controlled trials of 19 therapeutic agents to determine the association between improvements in BMD and reductions in fracture risk. We used a linear model to examine the relationship between mean percent difference in BMD change between treatment and placebo groups and the logarithm of the relative risk. We found that greater improvements in BMD were strongly associated with greater reductions in vertebral and hip fractures but not nonvertebral fractures. For vertebral fracture, the r2 values for total hip, femoral neck, and lumbar spine BMD change were 0.56, 0.54, and 0.63, respectively (p ≤ 0.0002). For a 2% or 6% improvement in total hip BMD, we might expect a 28% or 66% reduction, respectively, in vertebral fracture risk. For hip fracture, the r2 values for total hip, femoral neck, and lumbar spine BMD change were 0.48 (p = 0.01), 0.42 (p = 0.02), and 0.22 (ns), respectively. For a 2% or 6% improvement in total hip BMD, we might expect a 16% or 40% reduction in hip fracture risk. In conclusion, our results extend prior observations that larger improvements in dual‐energy X‐ray absorptiometry (DXA)‐based BMD are associated with greater reductions in fracture risk, particularly for vertebral and hip fractures. Although these results cannot be directly applied to predict the treatment benefit in an individual patient, they provide compelling evidence that improvements in BMD with osteoporosis therapies may be useful surrogate endpoints for fracture in trials of new therapeutic agents. © 2019 American Society for Bone and Mineral Research.